Zur prognostischen Relevanz der Proliferationsmarker Ki-67 (MIB 1), PCNA und p53 bei kombiniert chirurgisch und radiologisch therapierten Karzinomen des Oropharynx und der Mundhöhle

Sittel, Christian; Ruiz, S.; Kvasnicka, H. M.; Volling, P.; Jungehülsing, M.; He, Eckel

doi:10.1055/s-2000-8788

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it was soon realised that PCNA is not at all proliferation specific, [15][16][17][18] and many studies revealed a poor correlation between this antigen and other proliferation markers, in addition to clinical parameters. [19][20][21][22] Consequently, PCNA staining is no longer recommended for use in surgical pathology. 20 23 24 During the past decade, several monoclonal and polyclonal antibodies against peptides from recombinant fragments of the Ki-67 antigen have been produced.…”

mentioning

confidence: 99%

Comparison of Ki-67 equivalent antibodies

Lindboe¹,

Torp²

2002

Journal of Clinical Pathology

View full text Add to dashboard Cite

Aims: To compare commercially available Ki-67 equivalent antibodies with regard to qualitative and quantitative immunohistochemical staining characteristics. Methods: The following antibodies were used: monoclonal MIB-1 (Immunotech), monoclonal MM1 (Novocastra), polyclonal NCL-Ki-67p (Novocastra), and polyclonal Rah Ki-67 (Dako). All immunostainings were evaluated in squamous epithelium from formalin fixed and paraffin wax embedded pharyngeal tonsils. Labelling indices (LIs) were recorded twice to test their reproducibility. Results: By application of all four antibodies the nuclear staining could be either diffuse, granular, or a combination of both (classified as granular in this study). The diffuse pattern generally showed a strong or moderate staining intensity, whereas the granular pattern displayed a continuum from strong to very weak, making it difficult to discriminate between positive and negative nuclei. The diffuse staining pattern was seen in approximately 59% of the nuclei with the MIB-1 antibody and in 35-45% when the other antibodies were used. The following mean LIs were recorded: MIB-1, 31%; NCL-Ki-67p, 21%; Rah Ki-67, 17%; and MM1, 14%. The reproducibility was excellent for all four antibodies, with the mean of differences between the two runs of counts ranging from 1.1% to 1.5%. Conclusions: The four tested Ki-67 equivalent antibodies revealed differences in qualitative and quantitative staining characteristics, which resulted in considerable variations in registered LIs. The MIB-1 antibody appears to have a higher sensitivity for detecting the Ki-67 antigen than the other three tested antibodies. These differences are important to consider when proliferative activity is determined by the Ki-67 LI.

show abstract

mentioning

confidence: 99%

Comparison of Ki-67 equivalent antibodies

Lindboe¹,

Torp²

2002

Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

“…В трех исследованиях, включавших в общей сложности 192 пациента, наблюдался незначительный прогностический эффект этого маркера [11]. Напротив, исследование, проведенное Sittel C. et al [16] показало, что высокая экспрессия Ki 67 является неблагоприятным фактором в прогнозе течения и общей безрецидивной выживаемости.…”

unclassified

Predictive diagnostics of lymph nodes metastatic lesion in patients with gastric adenocarcinoma

Кутилин¹,

Tatimov²,

Maslov³

et al. 2018

Med. vestn. Ûga Ross.

View full text Add to dashboard Cite

Ростовский научно-исследовательский онкологический институт, Ростов-на-Дону, Россия Цель: поиск маркеров для прогнозирования вероятности развития метастазов при аденокарциноме желудка. Материалы и методы: использовали ткани 47 пациентов с диагнозом аденокарцинома желудка: с локализованной формой опухоли T3-4N0M0 (n=18) и местнораспространенной формой T3-4N1-3M0 (n=29). Методом RT-PCR определяли копийность 16 генов (APC,

show abstract

Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value

Tannapfel

Weber

2001

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

Despite recent advances in tumor surgery and multimodal treatment regimens the prognosis of squamous cell carcinomas of the head and neck is still relatively poor and has shown only slow progress. Additional clinical and biological factors are therefore urgently needed that aid tumor diagnosis, early detection of tumor recurrences, prediction of the results of therapeutic interventions, and identification of subsets of patients with unfavorable outcome during follow-up. A tumor marker should fulfill the criteria of specificity and clinical effectiveness. So far none of the known serological and biological markers fits all these criteria. Although some biological markers can be determined serologically without the need for tumor tissue, their low specificity limits their applicability to early detection of tumor recurrences during follow-up. A large number of molecular or genetic markers have been examined in squamous cell carcinomas of the head and neck. All of these are controversial regarding their prognostic value and clinical effectiveness. UICC tumor stage and patient's age and performance still remain the basis for therapeutic decisions. Further search for more sensitive and specific markers is needed to improve individual treatment and prognostic statements.

show abstract

Zur prognostischen Relevanz der Proliferationsmarker Ki-67 (MIB 1), PCNA und p53 bei kombiniert chirurgisch und radiologisch therapierten Karzinomen des Oropharynx und der Mundhöhle

Cited by 5 publications

References 21 publications

Comparison of Ki-67 equivalent antibodies

Comparison of Ki-67 equivalent antibodies

Predictive diagnostics of lymph nodes metastatic lesion in patients with gastric adenocarcinoma

Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value

Contact Info

Product

Resources

About